In This Webinar...
Data leaders and transparency leaders in the pharma industry are increasingly embracing a digital shift in which clinical trial data is reused for new benefits, including future trial design. As the industry tackles the cost of R&D and strives for innovation, bringing new life to clinical trial data is increasingly relevant. As data are reused for new benefits beyond a single trial, cultural, policy, and privacy challenges must be addressed alongside technological advancements in making data findable, accessible, interoperable, and reusable (FAIR).
At the conclusion of this webinar, participants should be able to understand:
- How clinical data can be safely reused for new benefits, including to accelerate drug R&D
- How to break down data silos organizationally, culturally, and technically
- How to build innovation networks and safely share data amongst innovation partners – further accelerating and enhancing the impact of digital innovations
- The complexity of reapplying data collected in clinical trials, and the opportunities to drive new insights by enhancing their accessibility
- How privacy and data anonymization with speed, scale, and precision underpin safe data reuse
- Learnings shared at the 2021 MIT CDOIQ Symposium keynote from Gabriel Eichler, VP of Data for the Novartis data42 program, on what high-performing data leaders and organizations have learned about data transformation.
||Sarah Lyons, Head of Privacy Analytics, Privacy Analytics|
||Gabriel Eichler, PhD., VP, Head of Data, Data42, Novartis|
|Aaron Mann, Senior Vice President, Data Science, Clinical Research Data Sharing Alliance|